Ani Pharmaceuticals (ANIP) Liabilities from Discontinued Operations (2012 - 2013)
Ani Pharmaceuticals (ANIP) reported Liabilities from Discontinued Operations of 131613.0 for Q3 2013, down 64.08% sequentially from 366390.0 in Q2 2013.
Ani Pharmaceuticals (ANIP) Liabilities from Discontinued Operations (2012 - 2013) Analysis & Trends
Ani Pharmaceuticals (ANIP) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 131613.0 in Q3 2013.
- For the quarter ending Q3 2013, Liabilities from Discontinued Operations changed N/A year-over-year to 131613.0; the trailing twelve-month figure through Sep 2013 stood at 131613.0 (changed N/A YoY), and the FY2012 full-year result was 370766.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations eased to 131613.0 in Q3 2013, from 366390.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 370766.0 in Q4 2012 to a low of 131613.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 131,613.00 |
| Sep 30, 2013 | 131,613.00 |
| Jun 30, 2013 | 366,390.00 |
| Jun 30, 2013 | 366,390.00 |
| Dec 31, 2012 | 370,766.00 |
| Dec 31, 2012 | 370,766.00 |